• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Establishment Labs Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    10/3/25 6:49:45 AM ET
    $ESTA
    Industrial Specialties
    Health Care
    Get the next $ESTA alert in real time by email
    esta-20250929
    Buiding B15 and 25Coyol Free ZoneAlajuelaCosta RicaNASDAQ5062434 24000001688757false00016887572025-09-292025-09-29

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934
    September 29, 2025
    Date of Report (date of earliest event reported)
    Establishment Labs Holdings Inc.
    (Exact name of registrant as specified in its charter)
    British Virgin Islands001-38593
    98-1436377
    (State or other jurisdiction of
    incorporation or organization)
    (Commission File No.)
    (I.R.S. Employer
    Identification Number)
    Buiding B15 and 25
    Coyol Free Zone
    Alajuela
    Costa Rica
    (Address of principal executive offices) (Zip Code)
    +506 2434 2400
    (Registrant’s telephone number, including area code)
    N/A
    (Former name or former address, if changed since last report)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading symbolName of each exchange on which registered
    Common Shares, No Par ValueESTA
    The NASDAQ Capital Market
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2) of this chapter.
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




    Item 1.01 Entry into a Material Definitive Agreement.

    On September 29, 2025, Establishment Labs Holdings Inc. (the “Company”) entered into a Fourth Amendment to Credit Agreement and Guaranty with Oaktree Fund Administration, LLC, as administrative agent, and the other parties thereto (the “Amendment”), which amends the terms of that certain Credit Agreement and Guaranty, dated as of April 26, 2022 (as amended, the “Agreement”). Capitalized terms used in this report and not otherwise defined have the definitions ascribed to them in the Agreement.

    The Amendment (i) provides for the availability of the Tranche D Term Loans to commence as of the effective date of the Amendment, notwithstanding the revenue milestone originally set forth in the Agreement, and (ii) increases, effective September 28, 2025, the minimum liquidity that the Company and its subsidiaries that are guarantors under the Agreement are required to maintain from $25,000,000 to $30,000,000.

    The foregoing description of the Amendment is not intended to be complete and is qualified in its entirety by reference to the Amendment attached as Exhibit 10.1 hereto.

    Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

    On September 29, 2025, the Company fully borrowed the Tranche D Term Loans available under the Agreement in an amount equal to $25,000,000.

    The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

    Exhibit No.Description
    10.1
    Fourth Amendment to Credit Agreement and Guaranty, dated as of September 29, 2025, by and among Establishment Labs Holdings Inc., its subsidiaries party thereto as guarantors, the lenders from time to time party thereto, and Oaktree Fund Administration, LLC, as administrative agent for the lenders.
    104Cover Page Interactive Data File (embedded within the Inline XBRL document)






    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
    ESTABLISHMENT LABS HOLDINGS INC.
    Dated:
    October 3, 2025
    By:
    /s/ Rajbir S. Denhoy
    Name:
    Rajbir S. Denhoy
    Title:
    Chief Financial Officer

    Get the next $ESTA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ESTA

    DatePrice TargetRatingAnalyst
    8/20/2025$60.00Buy
    Canaccord Genuity
    5/16/2025$62.00Buy
    BTIG Research
    5/14/2025$48.00Hold → Buy
    Needham
    4/14/2025Hold
    Needham
    5/22/2024$60.00Buy → Neutral
    Citigroup
    8/31/2023$75.00Overweight
    JP Morgan
    6/29/2023$79.00Buy
    Citigroup
    10/14/2022$90.00Overweight
    Stephens
    More analyst ratings

    $ESTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Schutter Edward J was granted 457 shares, increasing direct ownership by 0.33% to 138,015 units (SEC Form 4)

    4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

    10/1/25 5:39:22 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    Director Slotkin Bryan was granted 396 shares, increasing direct ownership by 1% to 29,748 units (SEC Form 4)

    4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

    10/1/25 5:39:04 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    Director Custin Ann was granted 503 shares, increasing direct ownership by 2% to 21,087 units (SEC Form 4)

    4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

    10/1/25 5:38:46 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    $ESTA
    SEC Filings

    View All

    Establishment Labs Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)

    10/3/25 6:49:45 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Establishment Labs Holdings Inc.

    SCHEDULE 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

    8/13/25 11:39:05 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    SEC Form 10-Q filed by Establishment Labs Holdings Inc.

    10-Q - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)

    8/7/25 5:24:07 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    $ESTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Establishment Labs with a new price target

    Canaccord Genuity initiated coverage of Establishment Labs with a rating of Buy and set a new price target of $60.00

    8/20/25 8:52:36 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    BTIG Research initiated coverage on Establishment Labs with a new price target

    BTIG Research initiated coverage of Establishment Labs with a rating of Buy and set a new price target of $62.00

    5/16/25 8:05:11 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Establishment Labs upgraded by Needham with a new price target

    Needham upgraded Establishment Labs from Hold to Buy and set a new price target of $48.00

    5/14/25 8:49:26 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    $ESTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Establishment Labs to Announce Third Quarter 2025 Financial Results on November 5

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended September 30, 2025, before the market opens on Wednesday, November 5, 2025, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or +1 (201) 689-8037 (International) and use conference ID number 13750830. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at ww

    10/22/25 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Establishment Labs Notes Publication of Mia Femtech 3-Year Prospective Study Results in Aesthetic Surgery Journal

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, noted the publication of "The 3-Year Results of a 100-Patient Prospective Study of Safety and Effectiveness of Mia Femtech" in the Aesthetic Surgery Journal. The study showed a very low rate of complications, with no reports of capsular contracture (Baker Grade III/IV), implant rupture (including a 33-patient MRI cohort), nipple or breast sensitivity loss, incision-related complications, infection, seroma, rippling, hematoma, or BIA-ALCL; the reoperation rate at 3 years was 1%. Patient and surgeon satis

    10/14/25 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Establishment Labs Publishes 15 Years of Motiva Data in 2025 Post-Market Surveillance Report

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced publication of its 2025 Post-Market Surveillance (PMS) Report. The report is being released ahead of the annual meeting of the American Society of Plastic Surgeons held October 9-12 in New Orleans. "Publishing our PMS report every year since the launch of Motiva in 2010 shows our dedication to accountability and transparency," said Peter Caldini, Establishment Labs Chief Executive Officer. "No other company in our industry publishes this level of information on an annual basis, and I would enc

    10/9/25 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    $ESTA
    Leadership Updates

    Live Leadership Updates

    View All

    Establishment Labs Publishes 15 Years of Motiva Data in 2025 Post-Market Surveillance Report

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced publication of its 2025 Post-Market Surveillance (PMS) Report. The report is being released ahead of the annual meeting of the American Society of Plastic Surgeons held October 9-12 in New Orleans. "Publishing our PMS report every year since the launch of Motiva in 2010 shows our dedication to accountability and transparency," said Peter Caldini, Establishment Labs Chief Executive Officer. "No other company in our industry publishes this level of information on an annual basis, and I would enc

    10/9/25 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Establishment Labs Appoints Peter Caldini as Chief Executive Officer

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today the appointment of Peter Caldini as Chief Executive Officer effective May 7, 2025. Mr. Caldini has served as Interim CEO since March 1, 2025, when Establishment Labs' Founder and previous CEO Juan José Chacón-Quirós retired from the role. "After an extensive search process, it was clear that with his deep operational, commercial, and financial skills, Peter is the ideal person to lead Establishment Labs," commented Nick Lewin, Chairman of the Board of Establishment Labs. "We have a vision

    5/7/25 4:00:00 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    Establishment Labs Announces CEO Transition

    Peter Caldini to become Interim CEO effective March 1, 2025 Establishment Labs also announces preliminary unaudited fourth quarter revenue in line with recent guidance Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness in breast aesthetics and reconstruction, announced today that after twenty years as Chief Executive Officer (CEO), Juan José Chacón-Quirós has decided to retire as CEO, effective March 1, 2025. Peter Caldini, currently President of Establishment Labs, will serve as Interim CEO after that date. Mr. Chacón-Quirós will continue with Establishment Labs as both a board member and an active

    1/13/25 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    $ESTA
    Financials

    Live finance-specific insights

    View All

    Establishment Labs to Announce Third Quarter 2025 Financial Results on November 5

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended September 30, 2025, before the market opens on Wednesday, November 5, 2025, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or +1 (201) 689-8037 (International) and use conference ID number 13750830. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at ww

    10/22/25 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Establishment Labs Reports Second Quarter 2025 Financial Results

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2025. Second Quarter Highlights and Outlook (Unaudited) Second quarter worldwide revenue of $51.3 million, an increase of 16.3% from the year ago period. Revenue included $10.3 million of Motiva sales in the United States. 2025 revenue guidance increased to $208 million to $212 million from $205 million to $210 million, year over year growth of 25%–28%, with at least $40 million in US Motiva revenue. Second quarter gross ma

    8/7/25 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Establishment Labs to Announce Second Quarter 2025 Financial Results on August 7

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2025, before the market opens on Thursday, August 7, 2025, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (416) 764 8646 (U.S. and Canada) or +1 (888) 396 8049 (International) and use conference ID number 13750829. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establ

    7/25/25 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    $ESTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Establishment Labs Holdings Inc.

    SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

    11/12/24 12:54:20 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Establishment Labs Holdings Inc.

    SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

    11/12/24 9:03:38 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Establishment Labs Holdings Inc. (Amendment)

    SC 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

    2/14/24 4:51:40 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    $ESTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lewin Nicholas Sheridan bought $98,410 worth of shares (2,600 units at $37.85) (SEC Form 4)

    4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

    8/14/25 10:58:27 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Director Lewin Nicholas Sheridan bought $78,880 worth of shares (2,300 units at $34.30) (SEC Form 4)

    4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

    8/13/25 11:02:28 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Amendment: Chief Executive Officer Caldini Filippo bought $100,320 worth of shares (2,850 units at $35.20), increasing direct ownership by 9% to 35,245 units (SEC Form 4)

    4/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

    8/11/25 4:02:37 PM ET
    $ESTA
    Industrial Specialties
    Health Care